PRESS RELEASE published on 07/23/2024 at 07:30, 1 year 6 months ago Inside Information / News release on accounts, results GenSight Biologics reports cash position of €6.9 million as of June 30, 2024, with potential over 100 vials available upon Q3 resumption of early access program. Company confirms sufficient working capital and successful blending step for LUMEVOQ drug product Working Capital Business Update Cash Position GenSight Biologics LUMEVOQ Drug Product
BRIEF published on 07/11/2024 at 07:35, 1 year 6 months ago GenSight Biologics Launches Newsletter for Retail Investors Financial Updates Gene Therapy Retail Investors LUMEVOQ® Optogenetics
PRESS RELEASE published on 07/11/2024 at 07:30, 1 year 6 months ago Inside Information / Other news releases GenSight Biologics launches a newsletter for retail investors providing updates, news articles, conferences, and financial figures in French, available via subscription on the company's website Subscription Retail Investors Newsletter French GenSight Biologics
BRIEF published on 06/20/2024 at 07:35, 1 year 7 months ago GenSight Biologics Renegotiates Financial Obligations and Provides Operational Updates Gene Therapy Operational Update GenSight Biologics Financial Negotiation
PRESS RELEASE published on 06/20/2024 at 07:30, 1 year 7 months ago Inside Information / Other news releases GenSight Biologics renegotiates financial obligations and provides operational updates, with successful capital increases enhancing short-term flexibility Financial Obligations Operational Updates GenSight Biologics Capital Increases Gene Therapies
BRIEF published on 06/04/2024 at 07:35, 1 year 7 months ago GenSight Biologics to Present at Key Medical Conferences in 2024 Gene Therapy GenSight Biologics Medical Conferences 2024 LUMEVOQ® LHON
PRESS RELEASE published on 06/04/2024 at 07:30, 1 year 7 months ago Inside Information / Other news releases GenSight Biologics to present at key medical and stakeholder meetings, including 16th Meeting of the EUNOS. Papers on LUMEVOQ® for LHON to be showcased Gene Therapy GenSight Biologics Medical Conferences LUMEVOQ Retinal Neurodegenerative Diseases
BRIEF published on 06/03/2024 at 07:35, 1 year 7 months ago GenSight Biologics Welcomes William Monteith to the Board of Directors Board Of Directors Nomination GenSight Biologics William Monteith Gene Therapies
BRIEF published on 05/23/2024 at 11:40, 1 year 8 months ago Crossing thresholds for GENSIGHT BIOLOGICS SA Actions Crossing Thresholds GenSight Biologics Armistice Capital Subscription Warrants
BRIEF published on 05/07/2024 at 19:34, 1 year 8 months ago GenSight Biologics Announces Availability of Prospectus for New Shares Listing on Euronext Paris Euronext Paris Capital Increase Gene Therapy Prospectus GenSight Biologics
Published on 01/29/2026 at 18:45, 1 hour 22 minutes ago Silver Spruce Appoints Vice-President of Exploration
Published on 01/29/2026 at 18:00, 2 hours 7 minutes ago PPX Mining Announces Grant of Restricted Share Units and Deferred Share Units
Published on 01/29/2026 at 17:00, 3 hours 7 minutes ago Sparta Reports on Delay in Filing Annual Financial Statements
Published on 01/29/2026 at 14:30, 5 hours 37 minutes ago Innodata Selected by Palantir to Accelerate Advanced Initiatives in AI-Powered Rodeo Modernization
Published on 01/29/2026 at 14:00, 6 hours 7 minutes ago Horizon Aircraft Partners with RAMPF to Manufacture the Fuselage for its Aircraft
Published on 01/29/2026 at 19:35, 32 minutes ago S&P Global (S&P) Assigns ‘A/A-1’ Ratings with a Positive Outlook to Africa Finance Corporation Reflecting its Robust Credit Profile
Published on 01/29/2026 at 19:03, 1 hour 3 minutes ago EQS-Adhoc: adidas reports record revenues in 2025 and launches share buyback
Published on 01/29/2026 at 18:19, 1 hour 48 minutes ago SFS receives SBTi validation for its climate targets
Published on 01/29/2026 at 18:00, 2 hours 7 minutes ago Waga Energy Reinforces its Board of Directors to Support its International Ambition
Published on 01/29/2026 at 18:00, 2 hours 7 minutes ago GUILLEMOT CORPORATION: FULL-YEAR 2025 CONSOLIDATED TURNOVER UP 2%
Published on 01/29/2026 at 17:45, 2 hours 22 minutes ago LANSON-BCC ANNOUNCES 2025 REVENUES AND FINALISES THE ACQUISITION OF HEIDSIECK & C° MONOPOLE
Published on 01/29/2026 at 17:45, 2 hours 22 minutes ago Cegedim generated LFL revenue growth of 1.1% in 2025
Published on 01/29/2026 at 10:07, 9 hours 59 minutes ago Deezer confirms demonetization of up to 85% of AI-music streams due to fraud and moves to sell AI-detection tech
